Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Application of Mechanistic Modeling to Support Dose-Relevant Decision Making for CAR-T Cell Therapy in Oncology: A Systematic Scoping Review.

Created on 06 Nov 2026

Authors

Dolapo Odujinrin, Graham McClelland

Published in

Clinical and translational science. Volume 19. Issue 11.

Abstract

CAR-T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose-relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response. These relationships are not adequately characterized by empirical dose escalation alone. Mechanistic modeling may offer a biologically interpretable way to connect preclinical evidence and patient-level CAR-T posology, but its application remains incompletely defined. We conducted a systematic scoping review using JBI methodology and PRISMA-ScR guidance, searching MEDLINE, Embase, Scopus, and Google Scholar (2010-2025). Eligible studies reported original CK/PD, PK/PD, QSP, PBPK/PD, stochastic, or agent-based models for dose-relevant application or regimen optimization. Nineteen studies met the inclusion criteria (13 mechanistic and 6 semi-mechanistic models) spanning hematologic and solid-tumor settings. Although these studies evaluated aspects of CAR-T pharmacology, none provided prospectively validated clinical dose-selection evidence. Overall, CAR-T expansion appeared to be more influenced by tumor burden, antigen engagement, product-specific attributes, lymphodepletion, and host or tumor-site factors than by nominal dose. Solid-tumor models highlighted delivery route, trafficking, biodistribution, and microenvironment barriers. Emerging in vivo CAR-T platforms shifted dose considerations toward vector or mRNA dose and repeat dosing. Mechanistic modeling appears useful for framing CAR-T dose-relevant and regimen questions, but the current evidence is best interpreted as a taxonomy of model applications rather than proof of prospective clinical dose selection utility. Consistent with ICH M15 principles, future clinical, and regulatory application will require defined context of use, stronger validation, uncertainty assessment, and biological integration.

PMID:
42992542
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement